| CAS NO: | 1181226-02-7 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 328.15 |
|---|---|
| Formula | C14H11Cl2NO4 |
| CAS No. | 1181226-02-7 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: ≥ 29 mg/mL |
| Water: <1 mg/mL | |
| Ethanol: | |
| Solubility (In vivo) | |
| Synonyms | ZL006; ZL-006; ZL 006. |
| In Vitro | In vitro activity: ZL006 presents little cytotoxicity, and a growth inhibition of BCECs is not found at low concentration of 0.001, 0.01, 0.1, 1 and 10 μg/mL. The cytotoxicity of T7-P-LPs/ZL006 is significantly enhanced at the concentration of 10 μg/mL. Cellular uptake of ZL006 loads P-LPs and T7-P-LPs after incubation for 0.5 h at the concentrations range from 100 μg/mL to 600 μg/mL in BCECs. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Compared with P-LPs/ZL006 and free ZL006, T7-P-LPs/ZL006 exhibits a significant increase of drug accumulation in the brain tissue due to its better brain targeting delivery. Compared with free ZL006, P-LPs/ZL006 and T7-P-LPs/ZL006 exhibit a significant decrease of drug accumulation in the liver and kidney |
| Animal model | |
| Formulation & Dosage | |
| References | Sci Rep. 2015 Jul 29;5:12651. Sci Rep. 2015 Jul 16;5:12157 |
m.cnreagent.com